Published: 5 February 2019
Author(s): Satoshi Higuchi, Shun Kohsaka, Yasuyuki Shiraishi, Toshiomi Katsuki, Yuji Nagatomo, Atsushi Mizuno, Yasumori Sujino, Takashi Kohno, Ayumi Goda, Tsutomu Yoshikawa, West Tokyo Heart Failure (WET-HF) Registry Investigators
Although guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) should be treated with renin-angiotensin system (RAS) inhibitors, the long-term efficacy of RAS inhibitors in HFrEF patients with moderate-to-severe chronic kidney disease (CKD) remains unclear.
